THURSDAY, Jan. 4, 2024 (HealthDay News) -- More than 20 percent of children with two or more medication exposures experience major drug-drug interactions (DDIs) annually, according to a study published online Jan. 4 in Pediatrics.
Kathryn E. Kyler, M.D., from Children's Mercy Kansas City in Missouri, and colleagues conducted a cross-sectional study of children aged 0 to 18 years with one or more ambulatory encounter and two or more dispensed outpatient prescriptions to examine the prevalence of major DDI exposure and factors associated with higher DDI exposure rates among children in an outpatient setting. Data were included for 781,019 children with two or more medication exposures.
The researchers found that 21.4 percent of the children experienced one or more major DDI exposures. Increased odds of DDI exposure were seen in association with age and with medical and mental health complexity. Clonidine, psychiatric medications, and asthma medications were frequently implicated drugs. Per 100 children included, the highest adverse physiologic effect exposure rate was for increased drug concentrations, central nervous system depression, and heart rate-corrected QT interval prolongation (14.6, 13.6, and 9.9, respectively).
"Prescribers should consider how and when to counsel patients about the risk of adverse drug events associated with DDIs, or when to simply monitor for adverse drug events in patients knowingly exposed to DDIs when the risk/benefit balance is favorable," the authors write.
Two authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
